Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
6
Issued Date
2024-12-01
Resource Type
eISSN
20597029
Scopus ID
2-s2.0-85210414722
Journal Title
ESMO Open
Volume
9
Issue
12
Rights Holder(s)
SCOPUS
Bibliographic Citation
ESMO Open Vol.9 No.12 (2024)
Suggested Citation
Lee S.H., Menis J., Kim T.M., Kim H.R., Zhou C., Kurniawati S.A., Prabhash K., Hayashi H., Lee D.D.W., Imasa M.S., Teh Y.L., Yang J.C.H., Reungwetwattana T., Sriuranpong V., Wu C.E., Ang Y., Sabando M., Thiagarajan M., Mizugaki H., Noronha V., Yulianti M., Zhang L., Smyth E., Yoshino T., Park J.O., Pentheroudakis G., Park S., Peters S., Ahn J.B., Popat S. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer. ESMO Open Vol.9 No.12 (2024). doi:10.1016/j.esmoop.2024.103996 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102282
Title
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
Author(s)
Lee S.H.
Menis J.
Kim T.M.
Kim H.R.
Zhou C.
Kurniawati S.A.
Prabhash K.
Hayashi H.
Lee D.D.W.
Imasa M.S.
Teh Y.L.
Yang J.C.H.
Reungwetwattana T.
Sriuranpong V.
Wu C.E.
Ang Y.
Sabando M.
Thiagarajan M.
Mizugaki H.
Noronha V.
Yulianti M.
Zhang L.
Smyth E.
Yoshino T.
Park J.O.
Pentheroudakis G.
Park S.
Peters S.
Ahn J.B.
Popat S.
Menis J.
Kim T.M.
Kim H.R.
Zhou C.
Kurniawati S.A.
Prabhash K.
Hayashi H.
Lee D.D.W.
Imasa M.S.
Teh Y.L.
Yang J.C.H.
Reungwetwattana T.
Sriuranpong V.
Wu C.E.
Ang Y.
Sabando M.
Thiagarajan M.
Mizugaki H.
Noronha V.
Yulianti M.
Zhang L.
Smyth E.
Yoshino T.
Park J.O.
Pentheroudakis G.
Park S.
Peters S.
Ahn J.B.
Popat S.
Author's Affiliation
National Hospital Organization Hokkaido Cancer Center
Rumah Sakit Kanker Dharmais
Oxford University Hospitals NHS Foundation Trust
Tongji University School of Medicine
Yonsei Cancer Hospital
Sun Yat-Sen University Cancer Center
Homi Bhabha National Institute
Chang Gung University College of Medicine
National Taiwan University Hospital
Lung Center of the Philippines
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
National Cancer Centre, Singapore
Kindai University School of Medicine
Universiti Malaya
Kuala Lumpur Hospital
Centre Hospitalier Universitaire Vaudois
Seoul National University Hospital
Samsung Medical Center, Sungkyunkwan university
The Royal Marsden NHS Foundation Trust
Faculty of Medicine Ramathibodi Hospital, Mahidol University
National Cancer Center Hospital East
Faculty of Medicine, Chulalongkorn University
Bicol Regional Hospital and Medical Center
University and Hospital Trust of Verona
ESMO
National University Cancer Institute
Rumah Sakit Kanker Dharmais
Oxford University Hospitals NHS Foundation Trust
Tongji University School of Medicine
Yonsei Cancer Hospital
Sun Yat-Sen University Cancer Center
Homi Bhabha National Institute
Chang Gung University College of Medicine
National Taiwan University Hospital
Lung Center of the Philippines
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
National Cancer Centre, Singapore
Kindai University School of Medicine
Universiti Malaya
Kuala Lumpur Hospital
Centre Hospitalier Universitaire Vaudois
Seoul National University Hospital
Samsung Medical Center, Sungkyunkwan university
The Royal Marsden NHS Foundation Trust
Faculty of Medicine Ramathibodi Hospital, Mahidol University
National Cancer Center Hospital East
Faculty of Medicine, Chulalongkorn University
Bicol Regional Hospital and Medical Center
University and Hospital Trust of Verona
ESMO
National University Cancer Institute
Corresponding Author(s)
Other Contributor(s)
Abstract
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), published in January 2023, was modified according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with oncogene-addicted mNSCLC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with oncogene-addicted mNSCLC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Korean Society for Medical Oncology (KSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with oncogene-addicted mNSCLC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, while respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between the different regions of Asia.